[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seizure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seizure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,79,113,139,170,208,229,255],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100627164","ai-based-mobile-intervention-on-medication-non-adherence-and-transition-100627164",false,"NCT07445074","AI-Based Mobile Intervention on Medication Non-Adherence and Transition","Inclusion Criteria:\n\n* Diagnosed with epilepsy\n* Currently prescribed anti-seizure medicine (ASMs)\n* Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)\n* Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study\n* Are between 18-24 years old and able to provide informed consent\n* Able to read, speak, and write in English\n* Resides in Florida\n* Receive outpatient medical services\n\nExclusion Criteria:\n\n* They do not own a mobile device with internet access.\n* They have a history of severe intellectual disability.\n* They are unable to operate a mobile device (keyboard or touchscreen).\n* Reside in an in-patient setting.\n* Adults unable to consent.\n* Pregnant women (excluded because pregnancy is not relevant to the study focus).\n* Prisoners.","ALL","14 Years","24 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA.\n\nOutcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.",[26,27],"Epilepsy","Seizure",[29,30,31,32,33,26,34,35,36,37,38],"Adherence","Anti-seizure medications","Artificial Intelligence","Chat-bot","Chronic disease","Mobile Applications","Self-management","Seizures","Transition","Underserved","RECRUITING","2026-05-27",{"date":42,"type":43},"2026-05-29","ACTUAL",{"date":45,"type":20},"2026-05",{"date":47,"type":20},"2026-12",{"name":49,"class":50},"University of Central Florida","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":15,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100627627","epileptiform-potential-of-fully-immersive-virtual-reality-100627627","NCT07451093","Epileptiform Potential of Fully Immersive Virtual Reality","Inclusion Criteria:\n\n* subjects with known or suspected diagnosis of epilepsy with interictal epileptiform discharges seen during current or prior EEG recording\n* Age greater than or equal to 13 years\n\nExclusion Criteria:\n\n* Age less than 13 years (infants, children)\n* Pregnancy\n* Incarceration\n* Moderate-severe cognitive impairment","13 Years",{"count":60,"type":20},40,[23],"The goal of this interventional study is to determine if the use of virtual reality headsets results in an increased risk of seizure in adolescent and adult individuals with epilepsy. The main question it aims to answer are:\n\n\\- does use of virtual reality headsets with hand controllers result in a higher risk of seizure compared to use of virtual reality headsets without hand controllers Participants will be asked to wear a virtual reality headset during continuous video EEG recording and EEG with be evaluated during three phases: with display turned off, with display turned on without hand controllers, and with display turned on with hand controllers.",[26,27],[26,27,65,66,67],"Virtual Reality","VR","Reflex epilepsy","NOT_YET_RECRUITING","2026-04-30",{"date":71,"type":43},"2026-05-06",{"date":73,"type":20},"2026-06",{"date":75,"type":20},"2027-06",{"name":77,"class":50},"Dartmouth-Hitchcock Medical Center",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100545959","phase-1-a-safety-tolerability-and-preliminary-efficacy-of-low-intensity-focused-ultrasound-neuromodulation-in-patients-with-drug-resistant-epilepsy-100545959","NCT06388707","A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy","A Prospective, Open-label, Single-arm, Multi-center, Pilot Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Unilateral or Bilateral Temporal Lobe Epilepsy","Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years of age at the time of enrollment.\n2. Patients with drug-resistant temporal lobe epilepsy (DR-TLE), defined as failure of adequate trials of two tolerated, appropriately chosen and used anti-epileptic drug schedules (whether as monotherapies or in combination).\n3. Focal-onset seizures with or without secondary generalization and no more than two known seizure onset zones (seizure foci), at least one which is in the mesial temporal lobe.\n4. At least 4 focal-onset seizures with objectively visible or significantly disabling manifestations in the 8-week baseline and at least one seizure per month in the baseline.\n5. MRI and EEG within the past 3 years. At least one prior EEG should demonstrate interictal or ictal focal epileptiform findings.\n6. Patients with the central of FUS exposure region are located at least 30 mm distance beneath the skull bone.\n7. Patients must be on a stable regimen of anti-epileptic drugs (AEDs) for at least 30 days at the time of enrollment, except for rescue benzodiazepines or occasional extra doses of ongoing medicines, as required.\n8. Females of childbearing potential must have a negative pregnancy test prior to the first treatment. Females of childbearing potential and male patients with a partner of childbearing potential must agree to follow acceptable method of contraception (as outlined below) from prior to the first study treatment to 3 months after the last study treatment. Standard acceptable methods include use of highly effective method of contraception, including: hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, spermicide, vasectomy, intrauterine device, and abstinence from sex.\n9. Patients are able and willing to have their hair shaved in the region where the coupling membrane will touch (or if they prefer, whole head).\n10. Patients are able to complete all clinical trial-related questionnaires in English, including with the use of a suitable interpreter.\n11. Patients or their legal representatives are able to provide written informed consent for participation in the trial and comply with study requirements in the opinion of the Investigator during the study period.\n\nExclusion Criteria:\n\n1. Patients who have primary generalized epilepsy, mixed focal and generalized epilepsy, or any history of non-epileptic seizures.\n2. Patients who have experienced tonic-clonic status epilepticus in the 12 months before the time of enrollment in the study. Subjects with focal status epilepticus may be considered at the discretion of the Investigator.\n3. The only feasible sonication pathway to the seizure onset zones involves either:\n\n   1. Skull area is covered by previous surgical site(s), scars, scalp disorders (e.g., eczema, psoriasis), or scalp atrophy.\n   2. Clips or other metallic implanted objects in the skull or brain, except shunts.\n   3. A prior craniotomy site.\n4. Patients with a potentially acute or progressive neurologic disorder (e.g., brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).\n5. Implanted electronic device, for example, implanted cardioverter-defibrillator (ICD), cardiac pacemaker, permanent medication pumps, cochlear implants, responsive neurostimulator, deep brain stimulation (DBS), or other electronic devices implanted in the brain. If a patient has a working Vagus Nerve Stimulator (VNS) in place, the settings should remain stable throughout the trial and the device will be turned off prior to each sonication treatment and then turned back on afterward.\n6. Patients with severe depression, active suicidal ideation or behavior (as per the C-SSRS), active psychosis (excluding time-limited postictal psychosis), or psychiatric hospitalization in the year before time of enrollment.\n7. Patient has an IQ \\\u003C 70, based on the Wechsler Abbreviated Scale of Intelligence (WASI-II or other Wechsler IQ measure).\n8. Coexisting medical problems of sufficient severity to limit compliance with or interpretation of the study.\n9. Patients have received an investigational drug or an investigational device within 4 weeks prior to the first treatment.\n10. Radiofrequency thermocoagulation (RFTC) within 2 months before time of enrollment.\n11. Known history of substance or alcohol abuse within the past year, not counting marijuana.\n12. Pregnant or breast-feeding women.\n13. Any other condition that, in the Investigator's judgment, might affect study endpoints or might increase the risk to the patients or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.","18 Years",{"count":88,"type":20},8,[90,91],"PHASE1","PHASE2","This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).",[94,26,95,27,96],"Drug Resistant Epilepsy","Seizures, Focal","Seizure Disorder",[98,99,100,101],"NaviFUS System","Focused Ultrasound","Low-Intensity Focused Ultrasound","LIFU","2026-04-06",{"date":104,"type":43},"2026-04-09",{"date":106,"type":43},"2024-09-13",{"date":108,"type":20},"2027-05-31",{"name":110,"class":111},"NaviFUS Corporation","INDUSTRY",3,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":123,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":112},"100601886","late-onset-seizures-trial-of-vascular-risk-investigation-and-treatment-100601886","NCT07116330","Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment","LOSTIT","Inclusion Criteria\n\nClinical study:\n\n\\- First assessment for unprovoked seizures or epilepsy with onset after age 50 -- - vascular risk factor evaluation per the new routine at participating care givers\n\nRegister study:\n\n* age ≥50 with a first-ever outpatient appointment to one of the participating clinics and\n* a first-listed diagnostic code for seizures or epilepsy (ICD-10: R568, G40)\n\nExclusion Criteria\n\nClinical study:\n\n* Inability to consent.\n* Progressive brain disease (tumour or degenerative)\n\nRegister study:\n\n* preexisting seizures\u002Fepilepsy, as demonstrated by a registered diagnostic code for seizures (ICD-10: R568, G40, G41) or a dispensed antiseizure medication (ATC-code: N03) more than 3 months before the initial consultation\n* a registered diagnostic code for stroke or TIA (ICD-10: I61, I63, I64, or G45 except G454) before the initial consultation, or\n* progressive brain disease, as indicated by diagnostic codes or drug prescriptions suggestive of brain tumors (ICD-10: C71, D33, D43, C793) or\n* neurocognitive disorders (ICD-10: F00-F03, F051, G30, G318, G912; ATC code: N06D).","50 Years",{"count":122,"type":20},420,"5 Years","OBSERVATIONAL","A growing body of evidence suggests patients with late-onset seizures are at an increased risk of stroke, but the potential for reducing cardiovascular morbidity through risk factor screening and management is unknown.\n\nThe investigators aim to determine whether individuals with new-onset unprovoked seizures after middle age should undergo vascular risk assessment. In a cluster project the investigators assess the effect of vascular risk factor screening in an observational study as well as a cohort study.\n\nThe project has two interlinked components: a prospective single group study, in which risk factor assessment is performed and subsequent management is followed for one year; and a register-based cohort study examining the long-term effects of the intervention on a system level.",[26,27],[128,129],"vascular risk","cardiovascular","2026-02-27",{"date":132,"type":43},"2026-03-03",{"date":134,"type":43},"2025-09-01",{"date":136,"type":20},"2035-06",{"name":138,"class":50},"Sahlgrenska University Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":156,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100609809","phase-2-a-long-term-study-of-the-safety-and-effectiveness-of-rap-219-in-adults-with-focal-onset-seizures-100609809","NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","70 Years",{"count":148,"type":20},30,[91],"This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[152,26,153,27,154,155],"Focal Epilepsy","Refractory Focal Epilepsy","Focal Seizure","Focal Onset Seizure",[157,26,158,159],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":162,"type":43},"2026-01-23",{"date":164,"type":43},"2025-12-15",{"date":166,"type":20},"2028-02-03",{"name":168,"class":111},"Rapport Therapeutics Inc.",7,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":177,"sex":15,"minAge":4,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":181,"conditions":182,"keywords":190,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":78},"100618256","investigating-phenotypic-epigenetic-and-neurogenetic-traits-in-rare-and-ultra-rare-neurodevelopmental-disorders-project-penguin-100618256","NCT07329257","Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)","Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders","For those with a rare condition:\n\nInclusion Criteria:\n\n* Diagnosed or suspected neurogenetic disorder\n* Individuals 0-99\n\nExclusion Criteria:\n\n* Individuals unwilling or unable to complete visits with the study team.\n\nFor control parents\u002Fcaregivers of those with a rare condition:\n\nInclusion Criteria:\n\n* No history of a neurological disorder.\n* \\>18 years.\n* Legal caregiver of the patient diagnosed with a rare neurodevelopmental disorder.\n\nExclusion Criteria:\n\n* Individuals unwilling or unable to complete the visit with the study team.\n* Individuals who have a history of neurological disorders.\n* \\\u003C 18 years old\n\nFor all individuals who participate in the skin biopsy:\n\n* Individuals with disease that is known to be associated with poor wound healing.\n* Individuals with a history of allergic reaction to lidocaine.\n* Medical History of cellulitis, diabetes mellitus, poor extremity circulation, deep vein thrombosis, or a history of non-traumatic amputation.\n* Currently taking anticoagulation or have taken with last 6 months",true,"99 Years",{"count":180,"type":20},100,"Rare genetic neurodevelopmental disorders, such as Syt-1 or Baker Gordon Syndrome (BAGOS) arise from mutations in genes essential for brain development and function, often disrupting neurotransmission and neuronal connectivity. These conditions present with a wide range of symptoms including developmental delays, seizures, motor and behavioral challenges, and vary widely in severity. These disorders are complex, and they remain poorly understood and lack effective treatments.\n\nNatural history and clinical genetic studies are crucial for mapping how these disorders progress, improving diagnostic accuracy, and guiding therapy development. A major focus is identifying reliable biomarkers (genetic, imaging, and physiological) to track disease severity and support clinical trials. This study will securely collect and analyze data to better understand disease impact, develop patient-derived model systems, and build resources to support future treatments.",[183,184,185,186,26,27,187,188,189],"Baker Gordon Syndrome","Rare Neurodevelopmental Conditions","Rare Neurogenetic Conditions","Syt-1 Disorder","Genetic Mutations","Autism in Children","Developmental Delay (Disorder)",[183,191,192,193,194,195,196,197,198],"BAGOS","Rare Conditions","Rare","Neurogenetic","Neurodevelopmental","Ultra-rare","Genetic mutation","Autism","2025-12-28",{"date":201,"type":43},"2026-01-09",{"date":203,"type":43},"2025-12-04",{"date":205,"type":20},"2028-12",{"name":207,"class":50},"University of Missouri-Columbia",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":15,"minAge":215,"maxAge":86,"enrollmentInfo":216,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100611528","predictors-of-drug-resistant-epilepsy-among-pediatric-patients-100611528","NCT07241754","Predictors of Drug Resistant Epilepsy Among Pediatric Patients","Predictors of Anti-seizure Medication Resistance in Pediatric Epilepsy","Inclusion Criteria:\n\n* Children aged 1-18 years with a confirmed diagnosis of epilepsy.\n* Both males and females will be included.\n\nExclusion Criteria:\n\n* Children younger than 1 year or older than 18 years.\n* Patients with acute symptomatic seizures (e.g., febrile seizures, metabolic or infectious causes) or pseudo refractory epilepsy (e .g. syncope or uncorrect ASMs)\n* Patients controlled on antiseizure medications\n* Refusal of parents or guardians to participate in the study","1 Year",{"count":19,"type":20},"1. This study aims to determine the main predictors of drug resistance in pediatric epilepsy by examining clinical data, EEG abnormalities, and neuroimaging results, in order to support early identification of resistant cases and improve treatment strategies .\n2. Early introduction of new lines of treatment in case of refractory epilepsy as : Ketogenic diet , Rituximab and solumedrol",[26,27,219],"Resistance","2025-12-09",{"date":222,"type":43},"2025-12-17",{"date":224,"type":20},"2025-12-29",{"date":226,"type":20},"2027-02-01",{"name":228,"class":50},"Assiut University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":15,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":51},"100600533","levetiracetam-versus-phenobarbital-in-benzodiazepines-unresponsive-paediatric-prolonged-seizures-100600533","NCT07098728","Levetiracetam Versus Phenobarbital in Benzodiazepines Unresponsive Paediatric Prolonged Seizures","Intravenous Levetiracetam Versus Intravenous Phenobarbital in Children With Prolonged Seizures Unresponsive to Benzodiazepines","Inclusion Criteria:\n\n* Children aged between 1 month to 12 years with prolonged seizures who do not respond to any two bolus doses of benzodiazepines\n\nExclusion Criteria:\n\n* Any of the following criteria will be excluded.\n\n  1. Children who receive anticonvulsant treatment other than benzodiazepines for the acute management of prolonged seizures\n  2. Acute symptomatic seizures due to hypertensive encephalopathy or hypoglycaemia\n  3. Presence of arrythmia or respiratory depression\n  4. Known case of chronic kidney disease or chronic liver disease","1 Month","12 Years",{"count":239,"type":20},180,[23],"Convulsive prolonged seizures in children are the most common life-threatening neurological emergencies. The aim of active management of seizure control is to prevent irreversible neuronal damage as early as possible. Although there is evidence of the use of benzodiazepines as the initial management for prolonged seizures, up to a third of patients do not respond to benzodiazepines. Many trials study the rate of seizures control among various second-line antiseizure medications (ASMs) in benzodiazepines unresponsive convulsive prolonged seizures. However, there is still few recommendations for paediatric population which drug is the most effective to control seizures rapidly and there is also a limited data on which drug has less adverse effects and is well tolerated. Currently, injection phenobarbital or levetiracetam is used as second-line antiseizure medication based on expert opinion in many centres globally including Yangon Children's Hospital. From this study, it is expected to identify the safer and more effective second-line treatment for prolonged seizures in children and be helpful in considering the alternative choice of appropriate medications in the management of prolonged seizures to include in the local guideline. A hospital-based randomized comparative study will be conducted at Yangon Children's Hospital. All children with benzodiazepines unresponsive prolonged seizures will be eligible for this study with the minimum sample size of 180 (90:90). Consecutive sample collection by block randomization will be done throughout the study period. The informed consent will be taken after explanation of nature, purposes, procedure, durations, benefits and risks. This study will be started with the approval of Academic Board of Study and Research and Ethics Committee, University of Medicine 1, Yangon. By this study, clinical response of intravenous levetiracetam versus intravenous phenobarbital in children with benzodiazepines unresponsive prolonged seizures will be evaluated. Aim of this study is to study the clinical response of intravenous levetiracetam versus intravenous phenobarbital in children with prolonged seizures unresponsive to benzodiazepines. Findings will support the choice of the safer and more effective second-line treatment for prolonged seizures in Myanmar children.\n\nAfter case selection according to inclusion criteria and getting informed consent, computerized block randomization will be done. Total 9 blocks will be generated with group A and group B. Each child will be assigned as group A or group B according to randomization. All patients will be received supportive care according to treatment guideline of the ward. Group A patients will be treated with intravenous levetiracetam 40 mg\u002Fkg (maximum of 3000 mg) over 15 minutes. Group B patients will be treated with intravenous phenobarbital 20 mg\u002Fkg (maximum of 1000 mg) over 20 minutes. Injection levetiracetam will be diluted with 5% dextrose water to a concentration of 50 mg\u002Fml. Injection phenobarbital will be diluted to become 20 ml with 5% dextrose water. All participants will also be monitored for oxygen saturation, respiratory rate and pattern, pulse rate, pulse volume, and blood pressure to detect treatment-related adverse effects. Monitoring will be conducted before, during, and 5 minutes after the assigned drug infusion, then hourly for 4 hours, every 2 hours for the following 4 hours, and every 4 hours thereafter.\n\nThe primary outcome of the study will be the clinical cessation of the seizure at five minutes after the completion of the infusion of intravenous levetiracetam or phenobarbital. The secondary outcome of the study will be the recurrence of seizure within 12 hours after the commencement of the study medications, need of other medications for active seizure control within 12 hours after the commencement of the study medications, need for rapid sequence induction (RSI) with thiopentone for on-going seizure management after administration of study medications. These secondary outcomes will be assessed in treatment-responsive groups. Treatment related adverse effects will also be assessed within five minutes of drug infusion in both treatment groups and within 12 hours in treatment-responsive groups. Data analysis will be done to compare the clinical response.\n\nIf the patient's seizure has stopped five minutes after completing the infusion of the assigned medication, a maintenance dose of either levetiracetam or phenobarbital, whichever was previously used, will be administered intravenously. If the patient is still experiencing seizure five minutes after completing the infusion of the assigned medication, the patient will be treated with an alternative second-line ASM. If the patient experiences serious treatment-related adverse effects within five minutes of the levetiracetam or phenobarbital infusion, the drug infusion will be stopped.",[27],[244],"Status Epilepticus","2025-07-29",{"date":247,"type":43},"2025-08-01",{"date":249,"type":43},"2025-07-22",{"date":251,"type":20},"2026-06-30",{"name":253,"class":254},"Ministry of Health and Sports, Myanmar","OTHER_GOV",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":15,"minAge":261,"maxAge":86,"enrollmentInfo":262,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100571682","assessment-of-pre-hospital-rescue-intervention-for-seizure-in-pediatric-patients-100571682","NCT06723431","Assessment of Pre Hospital Rescue Intervention for Seizure in Pediatric Patients","Inclusion Criteria:\n\n* Patient with recurrent attack of seizure and with prolonged seizure with prescribed treatment at home.\n* Patients aged from 2 years to 18 years\n\nExclusion Criteria:\n\n* First attack of seizure\n* condition mimic epilepsy","2 Years",{"count":263,"type":20},50,"1. Evaluation of pre hospital rescue intervention of seizure management.\n2. To investigate the type of rescue medication, Efficacy, route of administration, Side effects of this drug, frequency and Indication of its use.",[27],[267],"seizure in pediatric patients","2024-12-04",{"date":270,"type":43},"2024-12-09",{"date":272,"type":20},"2025-01",{"date":274,"type":20},"2025-11",{"name":228,"class":50}]